Johnson & Johnson http://www.jnj.com/
Robert Wood Johnson
concluded there ought to be a better way. Mr. Johnson joined with
his two brothers, James Wood and Edward Mead Johnson, who had
formed a partnership in 1885. Operations began in New Brunswick,
New Jersey, in 1886 with 14 employees on the fourth floor of a
small building that once was a wallpaper factory. In 1887 the
Company was incorporated as Johnson & Johnson.
Johnson & Johnson
went from a privately-held company to one publicly traded on the
New York Stock Exchange in 1944.
In 1982 and again in 1986
TYLENOL®, a product of our McNeil Consumer
& Specialty Pharmaceuticals subsidiary, was altered by
unknown individuals who placed deadly cyanide in the capsule form
of the product. The result was the death of seven people in 1982.
The product was voluntarily recalled and Johnson & Johnson
took a $100 million charge against earnings.
& Johnson Pfizer発表 Pfizer方針
Johnson to Acquire Pfizer Consumer Healthcare; Combination
Creates World's Premier Consumer Health Care Company
All Cash Transaction is Valued at $16.6 Billion
Johnson & Johnson,
the world's most comprehensive and broadly based manufacturer of
health care products, today announced that it has entered into a
definitive agreement to acquire Pfizer Consumer
billion in cash.
The Johnson & Johnson Board of Directors has given approval
to the transaction. Closing is subject to customary clearances,
including the Hart-Scott-Rodino Antitrust
and European Union merger control regulation. The transaction is
expected to close by the end of 2006.
The Pfizer Consumer Healthcare business adds a diverse portfolio
of strong, growing, enduring brands that provide Johnson &
Johnson with leadership positions in nine
additional categories, including large new segments such as
smoking cessation and mouthwash.
The combined portfolio of OTC brands will solidify the global
market-leading position of Johnson & Johnson's OTC franchise.
Under the terms of the agreement, Johnson & Johnson will also
acquire the U.S. OTC switch rights to ZYRTEC - Pfizer's once-a-day,
non-sedating prescription antihistamine抗ヒスタミン剤, upon patent expiration.
Pfizer Reaches Agreement to Sell Its Consumer
Healthcare Business to Johnson & Johnson for $16.6
||Company Will Use After-Tax
Proceeds to Invest in New Products and Innovative
Technologies and Enhance Shareholder Returns
||Pfizer Now Expects to
Purchase up to $17 Billion in Stock in 2006-7
||CEO McKinnell: 'We Have
Taken Another Important Step to Create Value for Our
Shareholders While Transforming Our Company'
Colleagues 'Have Done a Superb Job in Building an
Pfizer Inc said today that it has reached a
definitive agreement to sell its Pfizer Consumer Healthcare
(PCH) business to Johnson & Johnson for $16.6 billion in
cash, resulting in about $13.5 billion in after-tax proceeds.
The agreement, approved by the Pfizer Board of
Directors, completes a review of strategic options
for the consumer business that Pfizer initiated in February.
Antitrust Improvements Actの概要
Jun 2, 2016 J&J
Johnson & Johnson Announces Agreement to
Acquire Vogue International
Acquisition Strengthens Position in Hair Care
Johnson & Johnson today announced that Johnson & Johnson Consumer Inc. has
entered into a definitive agreement to acquire Vogue
International, a privately held company focused on the marketing,
development and distribution of salon-influenced and nature inspired
hair care and other personal care products, for
approximately $3.3 billion in cash. The acquisition
will include the OGX® collection of shampoos, conditioners, treatments, styling
products, body care and bath products, the FX™ line of hair styling products,
and the Proganix® and Maui Moisture hair care lines.
"Our acquisition of Vogue International's full line of leading advanced hair
care products sold in the U.S. and in 38 countries will strengthen our global
presence in this important category. Vogue International's commitment to
quality, innovation, and consumer preference complement our Consumer portfolio,
while also presenting attractive hair care category growth opportunities for
Johnson & Johnson," said Jorge Mesquita, Worldwide Chairman, Consumer, Johnson &
The closing is subject to antitrust clearance and other customary closing
conditions. The transaction is expected to close during the third quarter of
Upon closing, the transaction is not expected to impact the 2016 sales or
earnings guidance ranges that Johnson & Johnson announced on April 19, 2016.
September 16, 2016
Johnson & Johnson Announces Agreement to Acquire Abbott Medical Optics
Johnson & Johnson today announced a
definitive agreement to acquire Abbott Medical Optics
(AMO), a wholly-owned subsidiary of Abbott Laboratories, for
$4.325 billion in cash. AMO reported sales of $1.1
billion for 2015. The acquisition will include ophthalmic products in three
business segments: cataract surgery白内障手術,
laser refractive surgery レーザー屈折矯正手術and
consumer eye health.
"Eye health is one of the largest, fastest growing and most underserved segments
in health care today,” said Ashley McEvoy, Company Group Chairman, responsible
for Johnson & Johnson’s Vision Care Companies. “With the acquisition of Abbott
Medical Optics’ strong and differentiated surgical ophthalmic portfolio, coupled
with our world-leading ACUVUE® contact lens business,
we will become a more broad-based leader in vision care. Importantly, with this
acquisition we will enter cataract surgery – one of the most commonly performed
surgeries and the number one cause of preventable blindness.”
AMO is a global leader in ophthalmic surgery and is known for world-class
intraocular lenses used in cataract surgery. The World Health Organization
estimates that approximately 20 million people are blind from age-related
cataracts and that there are at least 100 million eyes with compromised visual
acuity 視力に影響するcaused by cataracts.
These numbers are steadily rising due to population growth and increasing life
In addition to the cataract business, AMO has advanced laser vision (LASIK)角膜屈折矯正手術
technologies designed to enhance surgeon productivity and correct near
sightedness, far sightedness and astigmatism. The acquisition also includes
AMO’s consumer eye health products – over-the-counter drops for dry eye, as well
as multipurpose solutions and hydrogen peroxide cleaning systems for patients
who wear contact lenses.
The transaction is expected to close in the first quarter of 2017 and would be
modestly accretive immediately to adjusted earnings per share*. The closing is
subject to antitrust clearance and other customary closing conditions. Following
the expected closing, sales will be reported in the Medical Devices segment as a
separate platform within Vision Care. not be considered a replacement for GAAP
The innovation began more than three decades
ago as the ophthalmic research arm of Heyer-Schulte
Medical Optics Center (HSMOC), a division of
American Hospital Supply Corporation. The HSMOC would later change its
name to American Medical Optics and eventually to Advanced
Medical Optics, or AMO, as it is known today.
The company started business in 1976 as a
pioneer in the early development of intraocular lenses (IOLs) for cataract
Throughout the 1980s, AMO became known as a
technology company, introducing innovative new IOLs, the first U.S.-made YAG
laser, and a first-generation phacoemulsification system, for the removal of
cataracts. A later generation of this technology, known as the SOVEREIGN®
System with WHITESTAR® technology, won the prestigious Medical Design
Excellence Silver Award from the Industrial Designers Society of America in 1999
for “excellence in medical product design engineering.”
In 1986, American
Medical Optics was sold to Allergan, Inc. and became known as
Allergan Medical Optics.
A few years later in 1989, the company
brought the first small-incision foldable IOL through the U. S. Food and Drug
Administration (FDA) regulatory process. Foldable lenses were a major advance in
cataract surgery because they made it possible for surgeons to insert the lens
through a small incision, resulting in less trauma to the eye and faster visual
recovery from cataract surgery, from months to days.
In 1997, AMO launched the Array®
IOL, the first multifocal lens to be approved for commercial distribution by the
AMO became an independent company in June
2002 following a spin-off from Allergan.
In 2004, AMO introduced the Verisyse phakic
IOL for treatment of moderate to severe myopia, the first lens of its kind to
receive FDA approval. The company also acquired the TECNIS® and CeeOn®
IOLs, the HEALON® line of viscoelastics and the BAERVELDT®
glaucoma device, marking the company's entrance into the glaucoma market. The
TECNIS® IOL is the first IOL with a modified prolate optic to have a
claim for improved functional vision.
On May 27, 2005, AMO completed the
acquisition of VISX, Incorporated, creating the world’s leading refractive
surgical business, bringing together AMO’s expansive suite of cataract and
refractive surgical products with VISX’s state-of-the-art laser vision
The growth continued in 2007 with the
addition of the industry’s leading wavefront diagnostic system and femotsecond
laser through the acquisitions of WaveFront Sciences and IntraLase Corp.,
These additions give AMO the advanced corneal refractive technologies with the
ability to offer a full systems approach that is without peer in the industry.
In 2009, Advanced
Medical Optics, Inc. was acquired by Abbott Laboratories. Today, AMO is
now Abbott Medical Optics Inc. and operated as a
separate entity within Abbott’s medical device division.
Nov. 25, 2016
Johnson & Johnson Confirms Discussions
with Actelion Regarding Potential Transaction
Johnson & Johnson today confirmed it is
engaged in preliminary discussions with Actelion
Pharmaceuticals Ltd. regarding a potential transaction.
There can be no assurance any transaction
will result from these discussions. Johnson & Johnson does not intend to
make any additional comments regarding these discussions unless and until it
is appropriate to do so, or a formal agreement has been reached.
confirmed today that it has been approached by Johnson & Johnson about a
There can be no
certainty that a transaction will result.
Actelion Ltd. is a
leading biopharmaceutical company focused on the discovery, development and
commercialization of innovative drugs for diseases with significant unmet
Actelion is a
leader in the field of pulmonary arterial hypertension (PAH 肺動脈性肺高血圧症). Our
portfolio of PAH treatments covers the spectrum of disease, from WHO Functional
Class (FC) II through to FC IV, with oral, inhaled and intravenous medications.
Although not available in all countries, Actelion has treatments approved by
health authorities for a number of specialist diseases including Type 1 Gaucher
diseaseゴーシェ病, Niemann-Pick type C diseaseニーマン・ピック病,
Digital Ulcers 指潰瘍
in patients suffering from systemic sclerosis, and
mycosis fungoides type cutaneous T-cell lymphoma菌状息肉腫型
Founded in late
1997, with now over 2,500 dedicated professionals covering all key markets
around the world including Europe, the US, Japan, China, Russia and Mexico,
Actelion has its corporate headquarters in Allschwil / Basel, Switzerland.
March 30, 2020
Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19;
Landmark New Partnership with U.S. Department of Health & Human Services; and
Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use
Johnson and BARDA Together Commit More than $1 Billion to Novel Coronavirus
Vaccine Research and Development;
Company Expects to Initiate Phase 1 Human Clinical
Studies of Vaccine Candidate at Latest by September 2020
Johnson & Johnson Will Establish New U.S. Vaccine Manufacturing Capabilities
and Additional Production Capacity Outside the U.S. to Begin Production at
Risk to Help Ensure Global Vaccine Supply
Johnson & Johnson
today announced the selection of a lead COVID-19 vaccine candidate from
constructs it has been working on since January 2020; the significant expansion
of the existing partnership between the Janssen
Pharmaceutical Companies of Johnson & Johnson and the
Biomedical Advanced Research and Development Authority (BARDA
and the rapid scaling of the Company’s manufacturing capacity with the goal of
providing global supply of more than one billion doses of a vaccine.
expects to initiate human clinical studies of its lead vaccine candidate at the
latest by September 2020 and anticipates the first batches of a COVID-19 vaccine
could be available for emergency use authorization in early 2021, a
substantially accelerated timeframe in comparison to the typical vaccine
Through a landmark new partnership, BARDA, which is part of the Office of the
Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department
of Health and Human Services, and Johnson & Johnson together have committed
more than $1 billion of investment to
co-fund vaccine research, development, and clinical
testing. Johnson & Johnson will use its validated vaccine platform and is
allocating resources, including personnel and infrastructure globally, as
needed, to focus on these efforts. Separately, BARDA and the Company have
provided additional funding that will enable expansion of their ongoing work to
identify potential antiviral treatments against the novel coronavirus.
As part of its commitment, Johnson & Johnson is also expanding the Company’s
global manufacturing capacity, including through the establishment of new
U.S. vaccine manufacturing capabilities and scaling up capacity in other
countries. The additional capacity will assist in the rapid production of a
vaccine and will enable the supply of more than one billion doses of a safe and
effective vaccine globally. The Company plans to begin production at risk
imminently and is committed to bringing an affordable vaccine to the public on a
not-for-profit basis for emergency pandemic use.
Alex Gorsky, Chairman and Chief Executive Officer, Johnson & Johnson, said, “The
world is facing an urgent public health crisis and we are committed to doing our
part to make a COVID-19 vaccine available and affordable globally as quickly as
possible. As the world’s largest healthcare company, we feel a deep
responsibility to improve the health of people around the world every day.
Johnson & Johnson is well positioned through our combination of scientific
expertise, operational scale and financial strength to bring our resources in
collaboration with others to accelerate the fight against this pandemic.”
Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief
Scientific Officer, Johnson & Johnson, said, “We greatly value the U.S.
government’s confidence and support for our R&D efforts. Johnson & Johnson’s
global team of experts has ramped up our research and development processes to
unprecedented levels, and our teams are working tirelessly alongside BARDA,
scientific partners, and global health authorities. We are very pleased to have
identified a lead vaccine candidate from the constructs we have been working on
since January. We are moving on an accelerated timeline toward Phase 1 human
clinical trials at the latest by September 2020 and, supported by the global
production capability that we are scaling up in parallel to this testing, we
expect a vaccine could be ready for emergency use in early 2021.”
Johnson & Johnson began efforts in January 2020, as soon as the novel
coronavirus (COVID-19) sequence became available, to research potential vaccine
candidates. Research teams at Janssen, in collaboration with Beth Israel
Deaconess Medical Center, part of Harvard Medical School, constructed and tested
multiple vaccine candidates using the Janssen AdVac®
Through collaborations with scientists at multiple academic institutions, the
vaccine constructs were then tested to identify those with the most promise in
producing an immune response in preclinical testing.
Based on this work, Johnson & Johnson has identified a
lead COVID-19 vaccine candidate (with two back-ups), which will progress
into the first manufacturing steps. Under an accelerated timeline, the Company
is aiming to initiate a Phase 1 clinical study in September 2020, with clinical
data on safety and efficacy expected to be available by the end of the year.
This could allow vaccine availability for emergency use in early 2021. For
comparison, the typical vaccine development process involves a number of
different research stages, spanning 5 to 7 years, before a candidate is even
considered for approval.
For more than 20 years, Johnson & Johnson has invested billions of dollars in
antivirals and vaccine capabilities. The COVID-19 vaccine program is leveraging
Janssen’s proven AdVac® and PER.C6® technologies that provide the ability to
rapidly develop new vaccine candidates and upscale production of the optimal
vaccine candidate. The same technology was used to develop and manufacture the
Company’s Ebola vaccine and construct our Zika, RSV, and HIV vaccine candidates
which are in Phase 2 or Phase 3 clinical development stages.
Expanded Antiviral Research
In addition to the vaccine development efforts, BARDA and Johnson & Johnson have
also expanded their partnership to accelerate Janssen’s ongoing work in
screening compound libraries, including compounds from other pharmaceutical
companies. The Company’s aim is to identify potential treatments against the
novel coronavirus. Johnson & Johnson and BARDA are both providing funding as
part of this partnership. These antiviral screening efforts are being conducted
in partnership with the Rega Institute for Medical Research (KU
Leuven/University of Leuven), in Belgium.
As announced in February 2020, the Company and BARDA have been working closely
with global partners to screen Janssen’s library of antiviral molecules to
accelerate the discovery of potential COVID-19 treatments.
COVID-19 belongs to a group of viruses called coronaviruses that attack the
respiratory system. There is currently no approved vaccine, treatment or cure
June 10, 2020
Johnson & Johnson Announces
Acceleration of its COVID-19 Vaccine Candidate; Phase 1/2a
Clinical Trial to Begin in Second Half of July
Johnson & Johnson today announced
that through its Janssen Pharmaceutical Companies it has
accelerated the initiation of the Phase 1/2a first-in-human clinical
trial of its investigational SARS-CoV-2 vaccine, Ad26.COV2-S,
recombinant. Initially scheduled to begin in September, the trial is now
expected to commence in the second half of July.
Paul Stoffels, M.D., Vice Chairman of
the Executive Committee and Chief Scientific Officer, Johnson & Johnson,
said, “Based on the strength of the preclinical data we have seen so far
and interactions with the regulatory authorities, we have been able to
further accelerate the clinical development of our investigational
SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant. Simultaneously, we are
continuing our efforts to build important global partnerships and invest
in our vaccine production technology and manufacturing capabilities. Our
goal is to ensure we can deliver a vaccine to the world and protect
people everywhere from this pandemic.”
The randomized, double-blind,
placebo-controlled Phase 1/2a study will evaluate the safety,
reactogenicity (response to vaccination), and immunogenicity (immune
response) of the investigational SARS-CoV-2 vaccine, Ad26.COV2-S,
recombinant in 1045 healthy adults aged 18 to 55 years, as well as
adults aged 65 years and older. The study will take place
in the U.S. and Belgium.
The Company is in discussions with
the National Institutes of Allergy and Infectious Diseases with the
objective to start the Phase 3 SARS-CoV-2 vaccine, Ad26.COV2-S,
recombinant, clinical trial ahead of its original schedule, pending
outcome of Phase 1 studies and approval of regulators.
As the Company progresses the
clinical development of its investigational SARS-CoV-2 vaccine,
Ad26.COV2-S, recombinant, it continues to increase
manufacturing capacity and is in active discussions with global
partners to ensure worldwide access. The Company committed to the goal
of supplying more than one billion doses globally
through the course of 2021, provided the vaccine is safe and
Johnson & Johnson’s efforts to
expedite development and production of a SARS-CoV-2 vaccine are enhanced
by a collaboration between Janssen and the Biomedical Advanced Research
and Development Authority (BARDA), part of the Office of the Assistant
Secretary for Preparedness and Response (ASPR) at the U.S. Department of
Health & Human Services.
COVID-19 is caused by SARS-CoV-2,
which belongs to a group of viruses called coronaviruses that attack the
respiratory system. There is currently no approved vaccine for COVID-19.
April 12, 2020
Johnson & Johnson
Suspends Plans Of Buying Japanese Pharmaceutical
Johnson & Johnson (J&J) suspended its plans of buying Takeda Pharmaceutical’s
TachoSil on Friday, April 10. The American multinational corporation cited
regulatory concerns for abandoning the deal.
Takeda Pharmaceutical is the largest drug manufacturer in Japan. Takeda had
revealed in May 2019 that J&J’s subsidiary, Ethicon, wishes to buy its surgical
patch that is used to control bleeding for £320 million (US$398.56 million).
Johnson’s representative was reported commenting on Friday, “Ethicon and Takeda
have mutually decided to terminate the TachoSil transaction, agreeing that it
was the right decision given the regulators’ concerns.”
Chairman Joseph Simons of the Federal Trade Commission (FTC) released a
statement earlier on Friday highlighting regulatory concerns regarding the
J&J-Takeda deal. Simons said that the regulatory issues stem from the fact that
J&J is the manufacturer of the only other fibrin sealant patch that is approved
for use in the United States. J&J’s patch is available in the US by the
name of Evarrest and is widely used during
surgeries to control bleeding.
According to Simons’ email, “Staff had significant concerns about the likely
anticompetitive effects and had recommended that the Commission block the
transaction. Now that the deal has been abandoned, patients and surgeons will
continue to benefit from competition.”
August 19, 2020
Johnson & Johnson to Acquire
Momenta Pharmaceuticals, Inc., Expanding Janssen’s Leadership in
Novel Treatments for Autoimmune Diseases
Acquisition Through an All-Cash Tender Offer of $52.50 Per
Nipocalimab Provides Opportunity for Janssen to Deliver
Transformative Treatments in Autoantibody-Driven Autoimmune
Cambridge, Massachusetts, Presence Increases J&J Footprint and
Capabilities in Key Innovation Hub
Johnson & Johnson today
announced it has entered into a definitive agreement to acquire
Momenta Pharmaceuticals, Inc., a company that discovers and develops
novel therapies for immune-mediated 免疫介在性の
diseases, in an all cash transaction for approximately
This acquisition provides an
opportunity for the Janssen Pharmaceutical Companies
of Johnson & Johnson to broaden its leadership in immune-mediated
diseases and drive further growth through expansion into autoantibody-driven
disease. The transaction will include full global rights to
a clinically validated, potentially best-in-class anti-FcRn antibody.
Nipocalimab gives Janssen the opportunity to reach significantly more
patients by pursuing indications across many autoimmune diseases with
substantial unmet medical need in maternal-fetal disorders, neuro-inflammatory
disorders, rheumatology, dermatology and autoimmune hematology. Nipocalimab
recently received a rare pediatric disease designation from the U.S. Food
and Drug Administration. Momenta’s expertise in FcRn mechanisms is
especially important for nipocalimab as it supports and accelerates the
development of a medicine designed to target a number of autoantibody-driven
conditions across several of Janssen’s established therapeutic areas.
Janssen expects nipocalimab to contribute to its goals of achieving
above-market growth over the mid and long term.
Autoimmune diseases driven
partially or completely by autoantibodies represent a novel area where
Janssen can significantly improve health outcomes for patients. In
autoantibody-driven diseases, the body’s antibodies attack or damage its own
proteins, cells and tissues, often with devastating consequences.
Autoantibody-driven diseases include Myasthenia Gravis, Hemolytic Diseases
of the Fetus and Newborn, warm Autoimmune Hemolytic Anemia, and other
serious dermatologic, rheumatic, neurologic, hematologic and renal diseases.
An estimated 2.5 percent of the population, or approximately 195 million
people worldwide, suffer from some form of autoantibody-driven disease, many
of which are orphan and rare diseases.
differentiated, parallel development programs and full worldwide commercial
rights for nipocalimab, Janssen will have the potential to introduce
multiple launches, many as first-in-class indications with potential for
significant peak year sales, some of which could exceed $1 billion,
supporting Janssen’s goal of continuing to deliver above-market performance
over the long term.
“This acquisition broadens
Janssen’s leadership in autoimmune diseases and provides us with a major
catalyst for sustained growth. Autoantibody-driven diseases are often
serious, and patients are underserved by current treatment options," said
Jennifer Taubert, Executive Vice President, Worldwide Chairman,
Pharmaceuticals, Johnson & Johnson. “We’re excited by the opportunity to
further advance patient care by combining Johnson & Johnson’s world-class
R&D, commercial and supply chain capabilities with Momenta’s talented
people, pipeline and deep expertise in this important area.”
In addition to Momenta’s
employees and lead asset nipocalimab, Janssen will acquire Momenta’s
pipeline of clinical and pre-clinical assets. The acquisition was driven by
the significant opportunity seen in nipocalimab, along with the scientific
capability Janssen is acquiring with the Momenta team. Janssen’s plans for
additional assets in the Momenta pipeline will be determined as more data
become available and could offer further upside potential.
“Nipocalimab, and the rest
of Momenta’s pipeline, built over many years by outstanding scientists who
have turned important insights into actionable biology, expands and
complements our portfolio by giving us clinical-stage and discovery-stage
compounds in autoantibody biological pathways. Combining Momenta’s
discoveries with our 20-year heritage in immunology, global scope, and
scientific and medical expertise, we see a real opportunity to create an
entire ‘pipeline in a pathway,’” said Mathai Mammen, M.D., Ph.D., Global
Head of Janssen Research & Development, Johnson & Johnson. “We are excited
about the significant potential to expand on Momenta’s excellent progress in
rare diseases, and to increase our impact on patients both within and beyond
our current focus areas.”
Janssen plans to retain
Momenta’s presence in Cambridge, Massachusetts. This site will increase
Johnson & Johnson’s existing innovation footprint and capabilities in the
greater Boston area given Momenta’s talented scientists, suite of
proprietary technologies, sophisticated laboratories and proximity to top
talent in this innovation hub.